AMENDMENTS TO THE CLAIMS

Please enter the following amendments without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims

Claims 1-40 (Cancelled)

Claim 41 (Previously Presented): The method of claim 65 wherein said RPE cells or cells of said population of non-RPE cells are attached to a matrix prior to administration.

Claim 42 (Previously Presented): The method of claim 65 wherein said RPE cells and cells of said population of non-RPE cells are attached to a matrix prior to administration.

Claim 43 (Cancelled)

Claim 44 (Previously Presented): The method of claim 65 wherein said RPE cells are administered in a dose ranging from 10^3 to 10^7 cells.

Claim 45 (Previously Presented): The method of claim 65 wherein said population of non-RPE cells is administered in a dose ranging from 10^3 to 10^7 cells.

Claim 46 (Previously Presented): The method of claim 65, further comprising re-administering RPE cells to the site in an effective amount to maintain the localized immunosuppression at the site and thereby sustain survival of the allogeneic non-RPE cells.

Claim 47 (Cancelled)

Claim 48 (Previously Presented): The method of claim 46 wherein the re-administered RPE cells are attached to a matrix prior to re-administration.

Claim 49 (Previously Presented): The method according to claim 65 wherein the RPE cells and the population of non-RPE cells are administered as a single composition.

Claim 50 (Previously Presented): The method according to claim 65 wherein the RPE cells and the population of non-RPE cells are administered as separate compositions.

Claim 51 -55 (Cancelled)

Claim 56 (Currently Amended): A pharmaceutical composition comprising retinal pigment epithelial (RPE) cells, a non-RPE cell population, and a pharmaceutically acceptable carrier, wherein said non-RPE cell population comprises insulin-producing β cells.

Claim 57 (Currently Amended): The composition of claim 56 wherein said insulin-producing β cells are pancreatic islet of Langerhans cells.

Claims 58-61 (Cancelled)

Claim 62 (Currently Amended): A compartmentalized kit adapted to receive a first container adapted to contain retinal pigment epithelial (RPE) cells and a second container adapted to contain a non-RPE cell population, wherein the non-RPE cell population comprises insulin-producing β cells.

Claim 63 (Currently Amended): The compartmentalized kit according to claim 62, wherein the insulin-producing β cells are pancreatic islet of Langerhans cells.

Claim 64 (Cancelled)

Claim 65 (Previously Presented): A method for facilitating survival of an allogeneic graft of a population of non-RPE cells in a mammal, comprising:

administering retinal pigment epithelial (RPE) cells and a population of non-RPE cells to a site in a mammal, wherein the population of non-RPE cells is allogeneic to the mammal, wherein the RPE cells secrete Fas L and wherein the RPE cells are administered in an amount effective to create localized immunosuppression at the site thereby increasing survival time of the allogeneic graft of the population of non-RPE cells in the mammal.

Claim 66 (Original): The method of claim 65 wherein said RPE cells are allogeneic to the mammal.

Claim 67 (Cancelled)

Claim 68 (Original): The method of claim 41 wherein said cells RPE cells are attached to a matrix prior to administration.

Claim 69 (Original): The method of claim 41 wherein said cells of said population of non-RPE cells are attached to a matrix prior to administration.

Claim 70 (Previously Presented): The composition of claim 56 wherein said RPE cells are attached to a matrix.

Claim 71 (Previously Presented): The composition of claim 56 wherein cells of said population of non-RPE cells are attached to a matrix.

Claim 72 (Currently Amended): An article of manufacture, comprising:

a packaging material;

retinal pigment epithelial (RPE) cells containing within said packaging material;

a non-RPE cell population contained within said packaging material, wherein the non-RPE cell population comprises insulin-producing β cells; and

wherein said packaging material contains a label that indicates that said RPE cells can be used for facilitating survival of an allogeneic graft of the non-RPE cell population in a mammal.

Claim 73 (Currently Amended): The article of manufacture according to claim 72, wherein the insulin-producing β cells are pancreatic islet of Langerhans cells.